CT perfusion in oncology: How to do it

Cancer Imaging

Volumn 10, Issue 1, 2010, Pages 8-19

  Petralia, G ^a   Bonello, L ^a   Viotti, S ^a   Preda, L ^a   D'Andrea, G ^a   Bellomi, Massimo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Body tumours; CT perfusion; Kinetic models; Oncology; Prediction of response to therapy; Therapy monitoring

Indexed keywords

IODINATED CONTRAST MEDIUM;

BREATH HOLDING; COMPUTED TOMOGRAPHY PERFUSION IMAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DATA ANALYSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; ORGAN PERFUSION; PATIENT MONITORING; REVIEW; TREATMENT RESPONSE; TUMOR LOCALIZATION; CANCER STAGING; DRUG MONITORING; IMAGE PROCESSING; INSTRUMENTATION; KINETICS; METHODOLOGY; NEOPLASM; PATHOPHYSIOLOGY; SCINTIGRAPHY; SCINTISCANNING; THEORETICAL MODEL;

DRUG MONITORING; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KINETICS; MODELS, THEORETICAL; NEOPLASM STAGING; NEOPLASMS; PERFUSION IMAGING;

EID: 77952311803     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2010.0001     Document Type: Review

References (74)

1. Jiao W, Xu J, Zheng J, Shen Y, Lin L, Li J. Elevation of circulating big endothelin-1: an independent prognostic factor for tumor recurrence and survival in patients with esophageal squamous cell carcinoma. BMC Cancer 2008; 8: 334. doi:10.1186/1471-2407-8-334. PMid:19014602.
2. Szarvas T, Jäger T, Droste F, et al. Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res 2009; 15: 193-201. doi:10.1007/s12253-008-9107-z.
3. Donnem T, Al-Saad S, Al-Shibli K, et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007; 13(22 Pt 1): 6649-57.
4. Rössler J, Taylor M, Geoerger B, et al. Angiogenesis as a target in neuroblastoma. Eur J Cancer 2008; 44: 1645-56.
5. Sahani DV, Holalkere NS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue - initial experience. Radiology 2007; 243: 736-43. doi:10.1148/radiol.2433052020. PMid:17517931.
6. Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A. CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 2007; 244: 486-93. doi:10.1148/radiol. 2442061189. PMid:17641369.
7. Sahani DV, Kalva SP, Hamberg LM, et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 2005; 234: 785-92. doi:10.1148/radiol.2343040286. PMid:15734934.
8. Sitartchouk I, Roberts HC, Pereira AM, Bayanati H, Waddell T, Roberts TP. Computed tomography perfusion using first pass methods for lung nodule characterization. Invest Radiol 2008; 43: 349-58. doi:10.1097/RLI. 0b013e3181690148. PMid:18496039.
9. Petralia G, Preda L, Giugliano G, et al. CT perfusion (CTp) for monitoring induction chemotherapy in patients with a squamous cell carcinoma of the upper aerodigestive tract: correlation between changes in tumor perfusion and tumor volume. J Comput Assist Tomogr 2009; 33: 552-9. doi:10.1097/RCT. 0b013e31818d446e. PMid:19638848.
10. Rumboldt Z, Al-Okaili R, Deveikis JP. Perfusion CT for head and neck tumors: pilot study. Am J Neuroradiol 2005; 26: 1178-85.
11. Zhang M, Kono M. Solitary pulmonary nodules: evaluation of blood flow patterns with dynamic CT. Radiology 1997; 205: 471-8.
12. Li Y, Yang ZG, Chen TW, Chen HJ, Sun JY, Lu YR. Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. Lung Cancer 2008; 61: 44-53. doi:10.1016/j.lungcan.2007.10. 021. PMid:18055062.
13. Ma SH, Le HB, Jia BH, et al. Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer 2008; 8: 186. doi:10.1186/1471-2407-8-186. PMid:18590539.
14. d'Assignies G, Couvelard A, Bahrami S, et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 2008; 250: 407-16. doi:10.1148/radiol.2501080291. PMid:19095784.
15. Feng ST, Sun CH, Li ZP, et al. Evaluation of microvessel density and vascular endothelial growth factor in colorectal carcinoma with 64-multidetector-row CT perfusion imaging. Zhonghua Wei Chang Wai Ke Za Zhi. 2008; 11: 537-41.
16. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7. doi:10.1038/nm988. PMid:14745444.
17. Goh V, Halligan S, Wellsted DM, Bartram CI. Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study. Eur Radiol 2009; 19: 79-89. doi:10.1007/s00330-008-1128-1. PMid:18704434.
18. Hermans R, Meijerink M, Van den Bogaert W, Rijnders A, Weltens C, Lambin P. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 1351-6.
19. Zima A, Carlos R, Gandhi D, Case I, Teknos T, Mukherji SK. Can pretreatment CT perfusion predict response of advanced squamous cell carcinoma of the upper aerodigestive tract treated with induction chemotherapy? AJNR Am J Neuroradiol 2007; 28: 328-34.
20. Wang J, Wu N, Cham MD, Song Y. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 2009; 193: 1090-6. doi:10.2214/AJR.08. 1367. PMid:19770333.
21. Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 2008; 13: 120-5. doi:10.1634/theoncologist.2007-0174. PMid:18305056.
22. Pandharipande PV, Krinsky GA, Rusinek H, Lee VS. Perfusion imaging of the liver: current challenges and future goals. Radiology 2005; 234: 661-73. doi:10.1148/radiol.2343031362. PMid:15734925.
23. Kiessling F, Boese J, Corvinus C, et al. Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? Eur Radiol 2004; 14: 1226-33.
24. Gandhi D, Chepeha DB, Miller T, et al. Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. Am J Neuroradiol 2006; 27: 101-6.
25. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008; 14: 6580-9. doi:10.1158/1078-0432.CCR-07-4310. PMid:18927299.
26. Xiong HQ, Herbst R, Faria SC, et al. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 2004; 22: 459-66. doi:10.1023/B:DRUG.0000036688.96453.8d. PMid:15292716.
27. Meijerink MR, van Cruijsen H, Hoekman K, et al. The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 2007; 17: 1700-13. doi:10.1007/s00330-006-0425-9. PMid:17072618.
28. McNeel DG, Eickhoff J, Lee FT, et al. Phase I trial of a monoclonal antibody specific for integrin (MEDI-522) in patients with advanced malignancies, including an assessment on tumor perfusion. Clin Cancer Res 2005; 11: 7851-60. doi:10.1158/1078-0432.CCR-05-0262. PMid:16278408.
29. Ng QS, Goh V, Carnell D, et al. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007; 67: 1375-80.
30. Ng QS, Goh V, Milner J, et al. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 2007; 8: 111-18. doi:10.1016/S1470-2045(07)70001-3.
31. Uusaro A, Ruokonen E, Takala J. Estimation of splanchnic blood flow by the Fick principle in man and problems in the use of indocyanine green. Cardiovasc Res 1995; 30: 106-12. doi:10.1016/0008-6363(95)00007-0.
32. Lee TY, Purdie TG, Stewart E. CT imaging of angiogenesis. Q J Nucl Med 2003; 47: 171-87.
33. Axel L. Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis. Radiology 1980; 137: 679-86.
34. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. Am J Neuroradiol 2000; 21: 462-70.
35. Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 2003; 76(suppl 1): S36-42. doi:10.1259/bjr/18486642. PMid:15456712.
36. Miles KA, Griffiths MR. Perfusion CT: a worthwhile enhancement? Br J Radiol 2003; 76: 220-31. doi:10.1259/bjr/13564625. PMid:12711641.
37. Miles KA, Charnsangavej C, Lee F, Fishman E, Horton K, Lee TY. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 2000; 7: 840-50. doi:10.1016/S1076-6332(00)80632-7.
38. Kambadakone AR, Sahani DV. Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am 2009; 47: 161-78. doi:10.1016/j.rcl.2008.11.003. PMid:19195541.
39. Platten D, Keat N, Lewis M, Edyvean S. 32 to 64 slice CT scanner: comparison report version 13. London: HMSO; 2005.
40. Goh V, Liaw J, Bartram CI, Halligan S. Effect of temporal interval between scan acquisitions on quantitative vascular parameters in colorectal cancer: implications for helical volumetric perfusion CT techniques. AJR Am J Roentgenol 2008; 191: W288-92. doi:10.2214/AJR.07.3985. PMid:19020217.
41. Miles KA. Functional computed tomography in oncology. Eur J Cancer 2002; 38: 2079-84. doi:10.1016/S0959-8049(02)00386-6.
42. Ng QS, Goh V, Milner J, Padhani AR, Saunders MI, Hoskin PJ. Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. Int J Radiat Oncol Biol Phys 2007; 67: 417-24.
43. Ng QS, Goh V, Fichte H, et al. Lung cancer perfusion at multidetector row CT: reproducibility of whole tumor quantitative measurements. Radiology 2006; 239: 547-53. doi:10.1148/radiol.2392050568. PMid:16543594.
44. Ng QS, Goh V, Klotz E, et al. Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage? AJR Am J Roentgenol 2006; 187: 1079-84. doi:10.2214/AJR.05.0889. PMid:16985160.
45. Bisdas S, Konstantinou GN, Lee PS, et al. Dynamic contrastenhanced CT of head and neck tumors: perfusion measurements using a distributed-parameter tracer kinetic model. Initial results and comparison with deconvolution-based analysis. . Phys Med Biol 2007; 52: 6181-96. doi:10.1088/0031-9155/52/20/007. PMid:17921579.
46. Gandhi D, Hoeffner EG, Carlos RC, et al. Computed tomography perfusion of squamous cell carcinoma of the upper aerodigestive tract. Initial results. J Comput Assist Tomogr 2003; 27: 687-93. doi:10.1097/00004728-200309000-00005. PMid:14501359.
47. Goh V, Halligan S, Hugill JA, et al. Quantitative colorectal cancer perfusion measurement using dynamic contrast-enhanced multidetector-row computed tomography: effect of acquisition time and implications for protocols. J Comput Assist Tomogr 2005; 29: 59-63. doi:10.1097/01.rct.0000152847.00257.d7. PMid:15665684.
48. Lee TY, Ellis RJ, Dunscombe PB, et al. Quantitative computed tomography of the brain with xenon enhancement: a phantom study with the GE9800 scanner. Phys Med Biol 1990; 35: 925-35. doi:10.1088/0031-9155/35/7/008. PMid:2385623.
49. Wintermark M, Maeder P, Verdun F, et al. Using 80 kVp versus 120 kVp in perfusion CT measurement of regional cerebral blood flow. AJNR Am J Neuroradiol 2000; 21: 1881-4.
50. Hirata M, Sugawara Y, Fukutomi Y, et al. Measurement of radiation dose in cerebral CT perfusion study. Radiat Med 2005; 23: 97-103.
51. Goh V, Halligan S, Gartner L, Bassett P, Bartram CI. Quantitative colorectal cancer perfusion measurement by multidetector-row CT: does greater tumour coverage improve measurement reproducibility? Br J Radiol 2006; 79: 578-83. doi:10.1259/bjr/18842556. PMid:16823062.
52. Goh V, Halligan S, Gharpuray A, Wellsted D, Sundin J, Bartram CI. Quantitative assessment of colorectal cancer tumor vascular parameters by using perfusion CT: influence of tumor region of interest. Radiology 2008; 247: 726-32. doi:10.1148/radiol.2473070414. PMid:18403621.
53. Goh V, Halligan S, Hugill JA, Bassett P, Bartram CI. Quantitative assessment of colorectal cancer perfusion using MDCT: inter- and intraobserver agreement. AJR Am J Roentgenol 2005; 185: 225-31.
54. Petralia G, Preda L, Raimondi S, et al. Intra- and interobserver agreement and impact of arterial input selection in perfusion CT measurements performed in squamous cell carcinoma of the upper aerodigestive tract. AJNR Am J Neuroradiol 2009; 30: 1107-15. doi:10.3174/ajnr.A1540. PMid:19342547.
55. Bisdas S, Baghi M, Smolarz A, et al. Quantitative measurements of perfusion and permeability of oropharyngeal and oral cavity cancer, recurrent disease, and associated lymph nodes using first-pass contrast-enhanced computed tomography studies. Invest Radiol 2007; 42: 172-9. doi:10.1097/01.rli. 0000252496.74242.0b. PMid:17287647.
56. Nabavi DG, Cenic A, Craen RA, et al. CT assessment of cerebral perfusion: experimental validation and initial clinical experience. Radiology 1999; 213: 141-9.
57. Hirata M, Sugawara Y, Murase K, Miki H, Mochizuki T. Evaluation of optimal scan duration end time in cerebral CT perfusion study. Radiat Med 2005; 23: 351-63.
58. Goh V, Halligan S, Bartram CI. Quantitative tumor perfusion assessment with multidetector CT - are measurements from two commercial software packages interchangeable? Radiology 2007; 242: 777-82. doi:10.1148/radiol.2423060279. PMid:17325066.
59. Goh V, Sanghera B, Wellsted DM, Sundin J, Halligan S. Assessment of the spatial pattern of colorectal tumour perfusion estimated at perfusion CT using two-dimensional fractal analysis. Eur Radiol 2009; 19: 1358-65. doi:10.1007/s00330-009-1304-y. PMid:19190914.
60. Chen Y, Zhang J, Dai J, Feng X, Lu H, Zhou C. Angiogenesis of renal cell carcinoma: perfusion CT findings. Abdom Imaging 2009. doi:10.1007/s00261-009- 9565-0.
61. Ash L, Teknos TN, Gandhi D, Patel S, Mukherji SK. Head and neck squamous cell carcinoma: CT perfusion can help non invasively predict intratumoral microvessel density. Radiology 2009; 251: 422-8. doi:10.1148/radiol.2512080743. PMid:19276321.
62. Goh V, Halligan S, Daley F, Wellsted DM, Guenther T, Bartram CI. Colorectal tumor vascularity: quantitative assessment with multidetector CT - do tumor perfusion measurements reflect angiogenesis? Radiology 2008; 249: 510-7. doi:10.1148/radiol.2492071365. PMid:18812560.
63. Li ZP, Meng QF, Sun CH, et al. Tumor angiogenesis and dynamic CT in colorectal carcinoma: radiologic-pathologic correlation. World J Gastroenterol 2005; 11: 1287-91.
64. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer 2001; 84: 1354-62. doi:10.1054/bjoc.2001.1809. PMid:11355947.
65. Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12: 303-24. doi:10.1007/BF00665960. PMid:8281615.
66. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
67. Dugdale PE, Miles KA. CT measurement of perfusion and permeability within lymphoma masses and its ability to assess grade, activity, and chemotherapeutic response. J Comput Assist Tomogr 1999; 23: 540-7. doi:10.1097/00004728- 199907000-00010. PMid:10433282.
68. Hayano K, Shuto K, Koda K, Yanagawa N, Okazumi S, Matsubara H. Quantitative measurement of blood flow using perfusion CT for assessing clinicopathologic features and prognosis in patients with rectal cancer. Dis Colon Rectum 2009; 52: 1624-9.
69. Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology 2003; 228: 63-9. doi:10.1148/radiol.2281011303. PMid:12775851.
70. Miller KD, Sweeney CJ, Sledge Jr GW. Redefining the target? chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19: 1195-206.
71. Kumar P, Benedict R, Urzua F, Fischbach C, Mooney D, Polverini P. Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. Lab Invest 2005; 85: 756-67. doi:10.1038/labinvest.3700272. PMid:15864318.
72. Lennernas B, Albertsson P, Lennernas H, Norrby K. Chemotherapy and antiangiogenesis: drug-specific, dose-related effects. Acta Oncol 2003; 42: 294-303. doi:10.1080/02841860310001835. (Pubitemid 36851146)
73. DePrimo SE, Bello C. Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol 2007; 18(Suppl 10): 11-9. doi:10.1093/annonc/mdm409. PMid:17761718.
74. Sabir A, Schor-Bardach R, Wilcox CJ, et al. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol 2008; 191: 133-9. doi:10.2214/AJR.07.2848. PMid:18562736.